163041-69-8

Basic information

• Product Name: 2-methoxy-3-(3-methylbut-2-en-1-yl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzaldehyde
• Synonyms: 2-methoxy-3-(3-methylbut-2-en-1-yl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzaldehyde
• CAS NO: 163041-69-8
• Molecular Weight: 304.386
• Mol File: 163041-69-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-methoxy-3-(3-methylbut-2-en-1-yl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxy-3-(3-methylbut-2-en-1-yl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzaldehyde(163041-69-8)
• EPA Substance Registry System: 2-methoxy-3-(3-methylbut-2-en-1-yl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzaldehyde(163041-69-8)

Safety Data

• Hazardous Substances Data: 163041-69-8(Hazardous Substances Data)

Upstream product

• 870-63-3 prenyl bromide 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 32268-30-7 2,4-dihydroxy-3-(3-methyl-2-but-en-1-yl)benzaldehyde 
• 163041-67-6 2-hydroxy-3-(3-methylbut-2-en-1-yl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzaldehyde 
• 74-88-4 methyl iodide 

Relevant articles and documents

Synthetic method for licochalcone C

According to the present invention, licochalcone C is produced by performing C-prenylation using A_2O_3, position selective deprotection and methylation, and general Claisen-Schmidt condensation under a base condition. A [3,3]-sigma bond position transferring reaction promoted by water cannot be applied to licochalcone C synthesis due to a decomposition problem. According to the present invention, it has been confirmed that position selective C-prenylation using Al_2O_3 is a novel method for synthesizing licochalcone C.COPYRIGHT KIPO 2015

Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.